Law Offices of Howard G. Smith announces it is investigating potential claims against the board of directors of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) concerning whether the board breached its fiduciary duties to shareholders.

IF YOU ARE A HIMS & HERS HEALTH, INC. (HIMS) SHAREHOLDER, CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@howardsmithlaw.com, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.

What Happened?

On February 7, 2026, The New York Times reported that the Company would stop selling its version of Wegovy, a popular weight loss drug by competitor Novo Nordisk. A former FDA commissioner was quoted as saying that Hims was “a different technology” than Novo Nordisk’s and that he is “not aware of any clinical trial data that suggests that the product that they wanted to sell actually worked using the technology that they used.”

Contact Us To Participate or Learn More:

If you still hold Hims shares purchased before December 2025 and wish to discuss this matter with us, or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Telephone: (215) 638-4847
Email: howardsmith@howardsmithlaw.com,
Visit our website at: www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260227160064/en/